Macquarie Group LTD Supernus Pharmaceuticals, Inc. Transaction History
Macquarie Group LTD
- $79.1 Billion
- Q2 2025
A detailed history of Macquarie Group LTD transactions in Supernus Pharmaceuticals, Inc. stock. As of the latest transaction made, Macquarie Group LTD holds 2,762,124 shares of SUPN stock, worth $156 Million. This represents 0.11% of its overall portfolio holdings.
Number of Shares
2,762,124
Previous 2,699,667
2.31%
Holding current value
$156 Million
Previous $88.4 Million
1.53%
% of portfolio
0.11%
Previous 0.11%
Shares
32 transactions
Others Institutions Holding SUPN
# of Institutions
318Shares Held
61MCall Options Held
18.4KPut Options Held
0-
Black Rock Inc. New York, NY10.4MShares$587 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA6.21MShares$351 Million0.0% of portfolio
-
Armistice Capital, LLC New York, NY4.81MShares$272 Million2.66% of portfolio
-
Dimensional Fund Advisors LP Austin, TX3.02MShares$171 Million0.02% of portfolio
-
State Street Corp Boston, MA2.21MShares$125 Million0.0% of portfolio
About SUPERNUS PHARMACEUTICALS, INC.
- Ticker SUPN
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 53,495,300
- Market Cap $3.02B
- Description
- Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prop...